Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction. [Review] (Record no. 10923)
[ view plain ]
| 000 -LEADER | |
|---|---|
| fixed length control field | 02487nam a22003617a 4500 |
| 008 - FIXED-LENGTH DATA ELEMENTS--GENERAL INFORMATION | |
| fixed length control field | 220511s20222022 xxu||||| |||| 00| 0 eng d |
| 022 ## - INTERNATIONAL STANDARD SERIAL NUMBER | |
| International Standard Serial Number | 1523-3790 |
| 024 ## - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/s11912-022-01234-y [doi] |
| 024 ## - OTHER STANDARD IDENTIFIER | |
| Standard number or code | 10.1007/s11912-022-01234-y [pii] |
| 040 ## - CATALOGING SOURCE | |
| Original cataloging agency | Ovid MEDLINE(R) |
| 099 ## - LOCAL FREE-TEXT CALL NUMBER (OCLC) | |
| PMID | 35362825 |
| 245 ## - TITLE STATEMENT | |
| Title | Cardioprotection for Anti-HER2 Therapy: Considerations for Primary Prevention and Use in Mildly Reduced Left Ventricular Ejection Fraction. [Review] |
| 251 ## - Source | |
| Source | Current Oncology Reports. 2022 Apr 01 |
| 252 ## - Abbreviated Source | |
| Abbreviated source | Curr Oncol Rep. 2022 Apr 01 |
| 253 ## - Journal Name | |
| Journal name | Current oncology reports |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Year | 2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Manufacturer | FY2022 |
| 260 ## - PUBLICATION, DISTRIBUTION, ETC. | |
| Publication date | 2022 Apr 01 |
| 265 ## - SOURCE FOR ACQUISITION/SUBSCRIPTION ADDRESS [OBSOLETE] | |
| Publication status | aheadofprint |
| 266 ## - Date added to catalog | |
| Date added to catalog | 2022-05-11 |
| 520 ## - SUMMARY, ETC. | |
| Abstract | PURPOSE OF REVIEW: This review summarizes current HER2-targeted therapies and clinical studies that have investigated primary and secondary prevention of cardiac dysfunction for HER2 + breast cancer patients undergoing targeted therapy. |
| 520 ## - SUMMARY, ETC. | |
| Abstract | RECENT FINDINGS: Primary and secondary prevention clinical trials highlight the importance of cardioprotective measures during HER2 + cancer treatment. Together, these studies suggest the safety of neurohormonal drugs, the importance for an individualized approach in starting cardiopreventive therapies, and the potential to expand HER2 + treatment options to patients with cardiac dysfunction. Cardiac dysfunction is a concerning adverse effect for HER2-targeted treatment. The goal of primary and secondary prevention is to prevent (further) cardiac function decline and heart failure symptoms, while delivering appropriate cancer therapy. Clinical trials investigating preventative therapies in the context of primary and secondary prevention are paving the path for reducing adverse cardiac effects and expanding treatment options for patients previously unable to undergo HER + therapy. Copyright © 2022. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| 546 ## - LANGUAGE NOTE | |
| Language note | English |
| 650 ## - SUBJECT ADDED ENTRY--TOPICAL TERM | |
| Topical term or geographic name entry element | IN PROCESS -- NOT YET INDEXED |
| 651 ## - SUBJECT ADDED ENTRY--GEOGRAPHIC NAME | |
| Institution | MedStar Heart & Vascular Institute |
| 657 ## - INDEX TERM--FUNCTION | |
| Medline publication type | Journal Article |
| 657 ## - INDEX TERM--FUNCTION | |
| Medline publication type | Review |
| 700 ## - ADDED ENTRY--PERSONAL NAME | |
| Local Authors | Barac, Ana |
| 790 ## - Authors | |
| All authors | Barac A, Zhang I |
| 856 ## - ELECTRONIC LOCATION AND ACCESS | |
| DOI | <a href="https://dx.doi.org/10.1007/s11912-022-01234-y">https://dx.doi.org/10.1007/s11912-022-01234-y</a> |
| Public note | https://dx.doi.org/10.1007/s11912-022-01234-y |
| 858 ## - ORCID | |
| ORCID text | Barac, Ana |
| Orcid | <a href="http://orcid.org/0000-0002-9935-8904">http://orcid.org/0000-0002-9935-8904</a> |
| Name | http://orcid.org/0000-0002-9935-8904 |
| 942 ## - ADDED ENTRY ELEMENTS (KOHA) | |
| Koha item type | Journal Article |
| Item type description | Article |
| Withdrawn status | Lost status | Damaged status | Not for loan | Collection | Home library | Current library | Date acquired | Total Checkouts | Full call number | Barcode | Date last seen | Price effective from | Koha item type |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| MedStar Authors Catalog | MedStar Authors Catalog | 05/11/2022 | 35362825 | 35362825 | 05/11/2022 | 05/11/2022 | Journal Article |